Forum Topic News
  • Conversation: FDA clears Amgen’s Prolia for glucocorticoid osteoporosis

    • May 23, 2018 1:01 PM BST
    • FDA clears Amgen’s Prolia for glucocorticoid osteoporosis

      US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
      The decision allows physicians to prescribe the drug to patients with a history of osteoporotic fracture, those with multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
      The approval is based on Phase III data showing that patients who received Prolia (denosumab) had greater gains in bone mineral density (BMD) compared to those who received its Actonel (risedronate).
      Read more: http://www.pharmatimes.com/news/fda_clears_amgens_prolia_for_glucocorticoid_osteoporosis_1236621

Add Reputation

Do you want to add reputation for this member by this post?

or cancel